Didadem Biotherapeutics is developing engineered exosomes through its DECOSTAR™ platform to activate immune receptors for the treatment of autoimmune conditions and cancers. This technology addresses the need for effective immunotherapy by enhancing agonist signaling to target validated therapeutic pathways.
Funding
Funding not disclosed
Founders
Product
Problem
Many autoimmune conditions and cancers could be treated by activating stimulatory immune receptors. However, achieving effective agonist signaling to target validated therapeutic pathways has proven challenging due to biophysical limitations.
Solution
Diadem Biotherapeutics is developing engineered exosomes through its DECOSTAR™ platform to address the challenges of agonist signaling and unlock the potential of immune receptor activation. The DECOSTAR™ platform enables the decoration of extracellular vesicles, allowing for targeted costimulatory activation or repression of immune cells. This approach aims to enhance the effectiveness of immunotherapy for autoimmune conditions and cancers by precisely tuning the immune response.
Target Audience
The primary target audience includes patients with autoimmune conditions and cancers who could benefit from enhanced immunotherapy approaches.
Features
- DECOSTAR™ platform for engineering exosomes with specific targeting and signaling properties.
- Targeted costimulatory activation of immune receptors.
- Potential for both activation and repression of immune cell functions.
- Designed to overcome biophysical challenges in agonist signaling.
- Focus on validated immunotherapy targets.